nodes	percent_of_prediction	percent_of_DWPC	metapath
Asenapine—HTR2B—Sorafenib—thyroid cancer	0.198	0.384	CbGbCtD
Asenapine—HTR2C—Sorafenib—thyroid cancer	0.129	0.25	CbGbCtD
Asenapine—CYP1A2—Sorafenib—thyroid cancer	0.0469	0.0909	CbGbCtD
Asenapine—CYP3A4—Vandetanib—thyroid cancer	0.0408	0.079	CbGbCtD
Asenapine—CYP2D6—Sorafenib—thyroid cancer	0.0387	0.0749	CbGbCtD
Asenapine—CYP3A4—Sorafenib—thyroid cancer	0.0246	0.0476	CbGbCtD
Asenapine—CYP2D6—Doxorubicin—thyroid cancer	0.0235	0.0454	CbGbCtD
Asenapine—CYP3A4—Doxorubicin—thyroid cancer	0.0149	0.0289	CbGbCtD
Asenapine—Glossodynia—Sorafenib—thyroid cancer	0.01	0.0347	CcSEcCtD
Asenapine—Electrocardiogram QT prolonged—Vandetanib—thyroid cancer	0.00771	0.0267	CcSEcCtD
Asenapine—Suicide—Sorafenib—thyroid cancer	0.00644	0.0223	CcSEcCtD
Asenapine—Completed suicide—Sorafenib—thyroid cancer	0.00568	0.0197	CcSEcCtD
Asenapine—Rhabdomyolysis—Sorafenib—thyroid cancer	0.00378	0.0131	CcSEcCtD
Asenapine—Dermatitis bullous—Vandetanib—thyroid cancer	0.00376	0.013	CcSEcCtD
Asenapine—Hyponatraemia—Vandetanib—thyroid cancer	0.00361	0.0125	CcSEcCtD
Asenapine—Skin exfoliation—Sorafenib—thyroid cancer	0.00319	0.011	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.00317	0.011	CcSEcCtD
Asenapine—Dysphagia—Vandetanib—thyroid cancer	0.00311	0.0108	CcSEcCtD
Asenapine—HTR5A—head—thyroid cancer	0.00308	0.132	CbGeAlD
Asenapine—Sinus tachycardia—Epirubicin—thyroid cancer	0.00306	0.0106	CcSEcCtD
Asenapine—Mouth ulceration—Sorafenib—thyroid cancer	0.00302	0.0105	CcSEcCtD
Asenapine—Gynaecomastia—Sorafenib—thyroid cancer	0.00299	0.0104	CcSEcCtD
Asenapine—Neutropenia—Vandetanib—thyroid cancer	0.00291	0.0101	CcSEcCtD
Asenapine—Sinus tachycardia—Doxorubicin—thyroid cancer	0.00284	0.00983	CcSEcCtD
Asenapine—Hyperglycaemia—Vandetanib—thyroid cancer	0.0028	0.00971	CcSEcCtD
Asenapine—Depression—Vandetanib—thyroid cancer	0.00276	0.00957	CcSEcCtD
Asenapine—Stomatitis—Vandetanib—thyroid cancer	0.0027	0.00936	CcSEcCtD
Asenapine—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00262	0.00908	CcSEcCtD
Asenapine—Bundle branch block—Epirubicin—thyroid cancer	0.00245	0.00848	CcSEcCtD
Asenapine—Hyponatraemia—Sorafenib—thyroid cancer	0.00243	0.00844	CcSEcCtD
Asenapine—Pain in extremity—Sorafenib—thyroid cancer	0.00242	0.0084	CcSEcCtD
Asenapine—Eye disorder—Vandetanib—thyroid cancer	0.00232	0.00805	CcSEcCtD
Asenapine—Cardiac disorder—Vandetanib—thyroid cancer	0.00231	0.008	CcSEcCtD
Asenapine—Bundle branch block—Doxorubicin—thyroid cancer	0.00226	0.00784	CcSEcCtD
Asenapine—Angiopathy—Vandetanib—thyroid cancer	0.00226	0.00782	CcSEcCtD
Asenapine—Mediastinal disorder—Vandetanib—thyroid cancer	0.00224	0.00777	CcSEcCtD
Asenapine—Breast disorder—Sorafenib—thyroid cancer	0.00219	0.00759	CcSEcCtD
Asenapine—Mental disorder—Vandetanib—thyroid cancer	0.00218	0.00755	CcSEcCtD
Asenapine—Malnutrition—Vandetanib—thyroid cancer	0.00216	0.0075	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.00214	0.00741	CcSEcCtD
Asenapine—Dysgeusia—Vandetanib—thyroid cancer	0.00212	0.00734	CcSEcCtD
Asenapine—Dysphagia—Sorafenib—thyroid cancer	0.0021	0.00726	CcSEcCtD
Asenapine—Muscle spasms—Vandetanib—thyroid cancer	0.00208	0.00721	CcSEcCtD
Asenapine—Tremor—Vandetanib—thyroid cancer	0.00203	0.00703	CcSEcCtD
Asenapine—Abdominal discomfort—Sorafenib—thyroid cancer	0.00201	0.00696	CcSEcCtD
Asenapine—Neutropenia—Sorafenib—thyroid cancer	0.00196	0.00679	CcSEcCtD
Asenapine—Loss of consciousness—Vandetanib—thyroid cancer	0.0019	0.00659	CcSEcCtD
Asenapine—Convulsion—Vandetanib—thyroid cancer	0.00188	0.0065	CcSEcCtD
Asenapine—Hypertension—Vandetanib—thyroid cancer	0.00187	0.00648	CcSEcCtD
Asenapine—Arthralgia—Vandetanib—thyroid cancer	0.00184	0.00639	CcSEcCtD
Asenapine—Anxiety—Vandetanib—thyroid cancer	0.00184	0.00636	CcSEcCtD
Asenapine—Stomatitis—Sorafenib—thyroid cancer	0.00182	0.00631	CcSEcCtD
Asenapine—Dry mouth—Vandetanib—thyroid cancer	0.0018	0.00625	CcSEcCtD
Asenapine—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00177	0.00612	CcSEcCtD
Asenapine—Nervous system disorder—Vandetanib—thyroid cancer	0.00173	0.006	CcSEcCtD
Asenapine—Thrombocytopenia—Vandetanib—thyroid cancer	0.00173	0.00599	CcSEcCtD
Asenapine—Blister—Epirubicin—thyroid cancer	0.00171	0.00593	CcSEcCtD
Asenapine—Connective tissue disorder—Sorafenib—thyroid cancer	0.00165	0.00571	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00161	0.00558	CcSEcCtD
Asenapine—Insomnia—Vandetanib—thyroid cancer	0.0016	0.00554	CcSEcCtD
Asenapine—Blister—Doxorubicin—thyroid cancer	0.00158	0.00549	CcSEcCtD
Asenapine—Dyspnoea—Vandetanib—thyroid cancer	0.00158	0.00546	CcSEcCtD
Asenapine—Cardiac disorder—Sorafenib—thyroid cancer	0.00156	0.00539	CcSEcCtD
Asenapine—Dyspepsia—Vandetanib—thyroid cancer	0.00156	0.00539	CcSEcCtD
Asenapine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00153	0.00528	CcSEcCtD
Asenapine—Fatigue—Vandetanib—thyroid cancer	0.00152	0.00528	CcSEcCtD
Asenapine—Angiopathy—Sorafenib—thyroid cancer	0.00152	0.00527	CcSEcCtD
Asenapine—Immune system disorder—Sorafenib—thyroid cancer	0.00152	0.00525	CcSEcCtD
Asenapine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00151	0.00524	CcSEcCtD
Asenapine—Constipation—Vandetanib—thyroid cancer	0.00151	0.00523	CcSEcCtD
Asenapine—Blood disorder—Epirubicin—thyroid cancer	0.00148	0.00512	CcSEcCtD
Asenapine—Mental disorder—Sorafenib—thyroid cancer	0.00147	0.00509	CcSEcCtD
Asenapine—Liver injury—Epirubicin—thyroid cancer	0.00147	0.00508	CcSEcCtD
Asenapine—Malnutrition—Sorafenib—thyroid cancer	0.00146	0.00506	CcSEcCtD
Asenapine—Dysgeusia—Sorafenib—thyroid cancer	0.00143	0.00495	CcSEcCtD
Asenapine—Amenorrhoea—Epirubicin—thyroid cancer	0.0014	0.00487	CcSEcCtD
Asenapine—Muscle spasms—Sorafenib—thyroid cancer	0.0014	0.00486	CcSEcCtD
Asenapine—Blood disorder—Doxorubicin—thyroid cancer	0.00137	0.00474	CcSEcCtD
Asenapine—Liver injury—Doxorubicin—thyroid cancer	0.00136	0.0047	CcSEcCtD
Asenapine—Anaemia—Sorafenib—thyroid cancer	0.00135	0.00468	CcSEcCtD
Asenapine—Angioedema—Sorafenib—thyroid cancer	0.00133	0.00462	CcSEcCtD
Asenapine—HTR1E—head—thyroid cancer	0.00132	0.0565	CbGeAlD
Asenapine—Dyskinesia—Epirubicin—thyroid cancer	0.00131	0.00455	CcSEcCtD
Asenapine—Syncope—Sorafenib—thyroid cancer	0.00131	0.00454	CcSEcCtD
Asenapine—Leukopenia—Sorafenib—thyroid cancer	0.00131	0.00453	CcSEcCtD
Asenapine—Ulcer—Epirubicin—thyroid cancer	0.00131	0.00452	CcSEcCtD
Asenapine—Dysarthria—Epirubicin—thyroid cancer	0.00131	0.00452	CcSEcCtD
Asenapine—Amenorrhoea—Doxorubicin—thyroid cancer	0.0013	0.0045	CcSEcCtD
Asenapine—Loss of consciousness—Sorafenib—thyroid cancer	0.00128	0.00445	CcSEcCtD
Asenapine—Inflammation—Epirubicin—thyroid cancer	0.00127	0.00441	CcSEcCtD
Asenapine—Asthenia—Vandetanib—thyroid cancer	0.00127	0.00439	CcSEcCtD
Asenapine—Hypertension—Sorafenib—thyroid cancer	0.00126	0.00437	CcSEcCtD
Asenapine—Arthralgia—Sorafenib—thyroid cancer	0.00124	0.00431	CcSEcCtD
Asenapine—Pulmonary embolism—Epirubicin—thyroid cancer	0.00123	0.00428	CcSEcCtD
Asenapine—Dry mouth—Sorafenib—thyroid cancer	0.00122	0.00421	CcSEcCtD
Asenapine—Dyskinesia—Doxorubicin—thyroid cancer	0.00122	0.00421	CcSEcCtD
Asenapine—Dysarthria—Doxorubicin—thyroid cancer	0.00121	0.00418	CcSEcCtD
Asenapine—Ulcer—Doxorubicin—thyroid cancer	0.00121	0.00418	CcSEcCtD
Asenapine—Salivary hypersecretion—Epirubicin—thyroid cancer	0.0012	0.00415	CcSEcCtD
Asenapine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00119	0.00413	CcSEcCtD
Asenapine—Skin exfoliation—Epirubicin—thyroid cancer	0.00118	0.00408	CcSEcCtD
Asenapine—Inflammation—Doxorubicin—thyroid cancer	0.00118	0.00408	CcSEcCtD
Asenapine—Shock—Sorafenib—thyroid cancer	0.00117	0.00406	CcSEcCtD
Asenapine—Nervous system disorder—Sorafenib—thyroid cancer	0.00117	0.00405	CcSEcCtD
Asenapine—Dizziness—Vandetanib—thyroid cancer	0.00117	0.00405	CcSEcCtD
Asenapine—Thrombocytopenia—Sorafenib—thyroid cancer	0.00117	0.00404	CcSEcCtD
Asenapine—Pulmonary embolism—Doxorubicin—thyroid cancer	0.00114	0.00396	CcSEcCtD
Asenapine—HTR7—neck—thyroid cancer	0.00114	0.0488	CbGeAlD
Asenapine—Vomiting—Vandetanib—thyroid cancer	0.00112	0.00389	CcSEcCtD
Asenapine—Mouth ulceration—Epirubicin—thyroid cancer	0.00112	0.00387	CcSEcCtD
Asenapine—Rash—Vandetanib—thyroid cancer	0.00111	0.00386	CcSEcCtD
Asenapine—Dermatitis—Vandetanib—thyroid cancer	0.00111	0.00386	CcSEcCtD
Asenapine—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.00111	0.00384	CcSEcCtD
Asenapine—Headache—Vandetanib—thyroid cancer	0.00111	0.00383	CcSEcCtD
Asenapine—Skin exfoliation—Doxorubicin—thyroid cancer	0.00109	0.00378	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00109	0.00376	CcSEcCtD
Asenapine—DRD3—head—thyroid cancer	0.00107	0.0461	CbGeAlD
Asenapine—Dyspnoea—Sorafenib—thyroid cancer	0.00106	0.00368	CcSEcCtD
Asenapine—Nausea—Vandetanib—thyroid cancer	0.00105	0.00364	CcSEcCtD
Asenapine—Dyspepsia—Sorafenib—thyroid cancer	0.00105	0.00363	CcSEcCtD
Asenapine—HTR6—head—thyroid cancer	0.00103	0.0443	CbGeAlD
Asenapine—Mouth ulceration—Doxorubicin—thyroid cancer	0.00103	0.00358	CcSEcCtD
Asenapine—Diabetes mellitus—Epirubicin—thyroid cancer	0.00103	0.00357	CcSEcCtD
Asenapine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00103	0.00356	CcSEcCtD
Asenapine—Fatigue—Sorafenib—thyroid cancer	0.00103	0.00356	CcSEcCtD
Asenapine—Constipation—Sorafenib—thyroid cancer	0.00102	0.00353	CcSEcCtD
Asenapine—Increased appetite—Epirubicin—thyroid cancer	0.000954	0.0033	CcSEcCtD
Asenapine—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000953	0.0033	CcSEcCtD
Asenapine—HRH2—head—thyroid cancer	0.000945	0.0405	CbGeAlD
Asenapine—Dermatitis bullous—Epirubicin—thyroid cancer	0.000938	0.00325	CcSEcCtD
Asenapine—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000926	0.00321	CcSEcCtD
Asenapine—Hyponatraemia—Epirubicin—thyroid cancer	0.0009	0.00312	CcSEcCtD
Asenapine—Osteoarthritis—Epirubicin—thyroid cancer	0.000896	0.0031	CcSEcCtD
Asenapine—Pain in extremity—Epirubicin—thyroid cancer	0.000896	0.0031	CcSEcCtD
Asenapine—Increased appetite—Doxorubicin—thyroid cancer	0.000883	0.00306	CcSEcCtD
Asenapine—Hypersensitivity—Sorafenib—thyroid cancer	0.000878	0.00304	CcSEcCtD
Asenapine—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000868	0.00301	CcSEcCtD
Asenapine—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000857	0.00297	CcSEcCtD
Asenapine—Asthenia—Sorafenib—thyroid cancer	0.000855	0.00296	CcSEcCtD
Asenapine—Hyponatraemia—Doxorubicin—thyroid cancer	0.000832	0.00288	CcSEcCtD
Asenapine—Osteoarthritis—Doxorubicin—thyroid cancer	0.000829	0.00287	CcSEcCtD
Asenapine—Pain in extremity—Doxorubicin—thyroid cancer	0.000829	0.00287	CcSEcCtD
Asenapine—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000818	0.00284	CcSEcCtD
Asenapine—Breast disorder—Epirubicin—thyroid cancer	0.00081	0.00281	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00079	0.00274	CcSEcCtD
Asenapine—Dizziness—Sorafenib—thyroid cancer	0.000788	0.00273	CcSEcCtD
Asenapine—Dysphagia—Epirubicin—thyroid cancer	0.000774	0.00268	CcSEcCtD
Asenapine—DRD1—head—thyroid cancer	0.000769	0.033	CbGeAlD
Asenapine—Vomiting—Sorafenib—thyroid cancer	0.000758	0.00263	CcSEcCtD
Asenapine—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000757	0.00262	CcSEcCtD
Asenapine—Rash—Sorafenib—thyroid cancer	0.000751	0.0026	CcSEcCtD
Asenapine—Dermatitis—Sorafenib—thyroid cancer	0.000751	0.0026	CcSEcCtD
Asenapine—Breast disorder—Doxorubicin—thyroid cancer	0.000749	0.0026	CcSEcCtD
Asenapine—Headache—Sorafenib—thyroid cancer	0.000747	0.00259	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000731	0.00253	CcSEcCtD
Asenapine—Neutropenia—Epirubicin—thyroid cancer	0.000724	0.00251	CcSEcCtD
Asenapine—Dysphagia—Doxorubicin—thyroid cancer	0.000717	0.00248	CcSEcCtD
Asenapine—HTR2A—neck—thyroid cancer	0.000709	0.0304	CbGeAlD
Asenapine—Nausea—Sorafenib—thyroid cancer	0.000708	0.00245	CcSEcCtD
Asenapine—Weight increased—Epirubicin—thyroid cancer	0.000705	0.00244	CcSEcCtD
Asenapine—Hyperglycaemia—Epirubicin—thyroid cancer	0.000699	0.00242	CcSEcCtD
Asenapine—HTR7—trachea—thyroid cancer	0.000684	0.0294	CbGeAlD
Asenapine—Stomatitis—Epirubicin—thyroid cancer	0.000673	0.00233	CcSEcCtD
Asenapine—Neutropenia—Doxorubicin—thyroid cancer	0.00067	0.00232	CcSEcCtD
Asenapine—HRH2—lymph node—thyroid cancer	0.000661	0.0284	CbGeAlD
Asenapine—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000653	0.00226	CcSEcCtD
Asenapine—Weight increased—Doxorubicin—thyroid cancer	0.000652	0.00226	CcSEcCtD
Asenapine—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000646	0.00224	CcSEcCtD
Asenapine—Agranulocytosis—Epirubicin—thyroid cancer	0.000644	0.00223	CcSEcCtD
Asenapine—HTR2B—thyroid gland—thyroid cancer	0.000632	0.0271	CbGeAlD
Asenapine—ADRA2C—trachea—thyroid cancer	0.000629	0.027	CbGeAlD
Asenapine—Stomatitis—Doxorubicin—thyroid cancer	0.000623	0.00216	CcSEcCtD
Asenapine—HTR1B—head—thyroid cancer	0.000623	0.0267	CbGeAlD
Asenapine—Oedema peripheral—Epirubicin—thyroid cancer	0.000611	0.00212	CcSEcCtD
Asenapine—Connective tissue disorder—Epirubicin—thyroid cancer	0.000609	0.00211	CcSEcCtD
Asenapine—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000604	0.00209	CcSEcCtD
Asenapine—HTR1D—head—thyroid cancer	0.000603	0.0259	CbGeAlD
Asenapine—HTR2C—head—thyroid cancer	0.000597	0.0256	CbGeAlD
Asenapine—Agranulocytosis—Doxorubicin—thyroid cancer	0.000596	0.00207	CcSEcCtD
Asenapine—ADRB1—head—thyroid cancer	0.000586	0.0251	CbGeAlD
Asenapine—Eye disorder—Epirubicin—thyroid cancer	0.000579	0.00201	CcSEcCtD
Asenapine—Cardiac disorder—Epirubicin—thyroid cancer	0.000575	0.00199	CcSEcCtD
Asenapine—SLC6A4—head—thyroid cancer	0.000566	0.0243	CbGeAlD
Asenapine—Oedema peripheral—Doxorubicin—thyroid cancer	0.000565	0.00196	CcSEcCtD
Asenapine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000564	0.00195	CcSEcCtD
Asenapine—Angiopathy—Epirubicin—thyroid cancer	0.000562	0.00195	CcSEcCtD
Asenapine—HTR2B—head—thyroid cancer	0.000561	0.0241	CbGeAlD
Asenapine—Immune system disorder—Epirubicin—thyroid cancer	0.00056	0.00194	CcSEcCtD
Asenapine—Mediastinal disorder—Epirubicin—thyroid cancer	0.000559	0.00194	CcSEcCtD
Asenapine—Mental disorder—Epirubicin—thyroid cancer	0.000543	0.00188	CcSEcCtD
Asenapine—Malnutrition—Epirubicin—thyroid cancer	0.00054	0.00187	CcSEcCtD
Asenapine—Eye disorder—Doxorubicin—thyroid cancer	0.000536	0.00186	CcSEcCtD
Asenapine—Cardiac disorder—Doxorubicin—thyroid cancer	0.000532	0.00184	CcSEcCtD
Asenapine—Dysgeusia—Epirubicin—thyroid cancer	0.000528	0.00183	CcSEcCtD
Asenapine—Angiopathy—Doxorubicin—thyroid cancer	0.00052	0.0018	CcSEcCtD
Asenapine—Muscle spasms—Epirubicin—thyroid cancer	0.000519	0.0018	CcSEcCtD
Asenapine—Immune system disorder—Doxorubicin—thyroid cancer	0.000518	0.0018	CcSEcCtD
Asenapine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000517	0.00179	CcSEcCtD
Asenapine—HRH1—trachea—thyroid cancer	0.000511	0.0219	CbGeAlD
Asenapine—HTR1A—head—thyroid cancer	0.000503	0.0216	CbGeAlD
Asenapine—Mental disorder—Doxorubicin—thyroid cancer	0.000503	0.00174	CcSEcCtD
Asenapine—ADRA2A—trachea—thyroid cancer	0.000502	0.0215	CbGeAlD
Asenapine—Malnutrition—Doxorubicin—thyroid cancer	0.000499	0.00173	CcSEcCtD
Asenapine—Anaemia—Epirubicin—thyroid cancer	0.000499	0.00173	CcSEcCtD
Asenapine—Agitation—Epirubicin—thyroid cancer	0.000496	0.00172	CcSEcCtD
Asenapine—Dysgeusia—Doxorubicin—thyroid cancer	0.000489	0.00169	CcSEcCtD
Asenapine—Malaise—Epirubicin—thyroid cancer	0.000487	0.00169	CcSEcCtD
Asenapine—Syncope—Epirubicin—thyroid cancer	0.000484	0.00168	CcSEcCtD
Asenapine—Leukopenia—Epirubicin—thyroid cancer	0.000483	0.00167	CcSEcCtD
Asenapine—HTR7—head—thyroid cancer	0.00048	0.0206	CbGeAlD
Asenapine—Muscle spasms—Doxorubicin—thyroid cancer	0.00048	0.00166	CcSEcCtD
Asenapine—Loss of consciousness—Epirubicin—thyroid cancer	0.000474	0.00164	CcSEcCtD
Asenapine—Convulsion—Epirubicin—thyroid cancer	0.000468	0.00162	CcSEcCtD
Asenapine—Hypertension—Epirubicin—thyroid cancer	0.000466	0.00161	CcSEcCtD
Asenapine—ADRA1A—head—thyroid cancer	0.000463	0.0199	CbGeAlD
Asenapine—Anaemia—Doxorubicin—thyroid cancer	0.000462	0.0016	CcSEcCtD
Asenapine—Arthralgia—Epirubicin—thyroid cancer	0.000459	0.00159	CcSEcCtD
Asenapine—Agitation—Doxorubicin—thyroid cancer	0.000459	0.00159	CcSEcCtD
Asenapine—Anxiety—Epirubicin—thyroid cancer	0.000458	0.00159	CcSEcCtD
Asenapine—DRD2—head—thyroid cancer	0.000454	0.0195	CbGeAlD
Asenapine—Malaise—Doxorubicin—thyroid cancer	0.00045	0.00156	CcSEcCtD
Asenapine—Dry mouth—Epirubicin—thyroid cancer	0.000449	0.00156	CcSEcCtD
Asenapine—Syncope—Doxorubicin—thyroid cancer	0.000448	0.00155	CcSEcCtD
Asenapine—Leukopenia—Doxorubicin—thyroid cancer	0.000447	0.00155	CcSEcCtD
Asenapine—ADRA2C—head—thyroid cancer	0.000441	0.0189	CbGeAlD
Asenapine—Anaphylactic shock—Epirubicin—thyroid cancer	0.00044	0.00153	CcSEcCtD
Asenapine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000439	0.00152	CcSEcCtD
Asenapine—Shock—Epirubicin—thyroid cancer	0.000433	0.0015	CcSEcCtD
Asenapine—Convulsion—Doxorubicin—thyroid cancer	0.000433	0.0015	CcSEcCtD
Asenapine—Nervous system disorder—Epirubicin—thyroid cancer	0.000432	0.0015	CcSEcCtD
Asenapine—CYP1A2—thyroid gland—thyroid cancer	0.000432	0.0185	CbGeAlD
Asenapine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000431	0.00149	CcSEcCtD
Asenapine—Hypertension—Doxorubicin—thyroid cancer	0.000431	0.00149	CcSEcCtD
Asenapine—Tachycardia—Epirubicin—thyroid cancer	0.00043	0.00149	CcSEcCtD
Asenapine—HTR2A—trachea—thyroid cancer	0.000427	0.0183	CbGeAlD
Asenapine—Arthralgia—Doxorubicin—thyroid cancer	0.000425	0.00147	CcSEcCtD
Asenapine—Anxiety—Doxorubicin—thyroid cancer	0.000424	0.00147	CcSEcCtD
Asenapine—Dry mouth—Doxorubicin—thyroid cancer	0.000416	0.00144	CcSEcCtD
Asenapine—Hypotension—Epirubicin—thyroid cancer	0.000412	0.00143	CcSEcCtD
Asenapine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000408	0.00141	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000401	0.00139	CcSEcCtD
Asenapine—Shock—Doxorubicin—thyroid cancer	0.000401	0.00139	CcSEcCtD
Asenapine—Nervous system disorder—Doxorubicin—thyroid cancer	0.0004	0.00138	CcSEcCtD
Asenapine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000399	0.00138	CcSEcCtD
Asenapine—Insomnia—Epirubicin—thyroid cancer	0.000398	0.00138	CcSEcCtD
Asenapine—Tachycardia—Doxorubicin—thyroid cancer	0.000398	0.00138	CcSEcCtD
Asenapine—ADRA2A—thyroid gland—thyroid cancer	0.000397	0.017	CbGeAlD
Asenapine—HTR2B—lymph node—thyroid cancer	0.000393	0.0169	CbGeAlD
Asenapine—Dyspnoea—Epirubicin—thyroid cancer	0.000393	0.00136	CcSEcCtD
Asenapine—Somnolence—Epirubicin—thyroid cancer	0.000392	0.00136	CcSEcCtD
Asenapine—Dyspepsia—Epirubicin—thyroid cancer	0.000388	0.00134	CcSEcCtD
Asenapine—Hypotension—Doxorubicin—thyroid cancer	0.000381	0.00132	CcSEcCtD
Asenapine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00038	0.00132	CcSEcCtD
Asenapine—Fatigue—Epirubicin—thyroid cancer	0.00038	0.00132	CcSEcCtD
Asenapine—Constipation—Epirubicin—thyroid cancer	0.000377	0.0013	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000371	0.00129	CcSEcCtD
Asenapine—Insomnia—Doxorubicin—thyroid cancer	0.000369	0.00128	CcSEcCtD
Asenapine—Dyspnoea—Doxorubicin—thyroid cancer	0.000363	0.00126	CcSEcCtD
Asenapine—Somnolence—Doxorubicin—thyroid cancer	0.000362	0.00126	CcSEcCtD
Asenapine—Dyspepsia—Doxorubicin—thyroid cancer	0.000359	0.00124	CcSEcCtD
Asenapine—HRH1—head—thyroid cancer	0.000359	0.0154	CbGeAlD
Asenapine—ADRA2A—head—thyroid cancer	0.000352	0.0151	CbGeAlD
Asenapine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000352	0.00122	CcSEcCtD
Asenapine—Fatigue—Doxorubicin—thyroid cancer	0.000351	0.00122	CcSEcCtD
Asenapine—Constipation—Doxorubicin—thyroid cancer	0.000348	0.00121	CcSEcCtD
Asenapine—Hypersensitivity—Epirubicin—thyroid cancer	0.000324	0.00112	CcSEcCtD
Asenapine—Asthenia—Epirubicin—thyroid cancer	0.000316	0.00109	CcSEcCtD
Asenapine—ADRA2C—lymph node—thyroid cancer	0.000309	0.0133	CbGeAlD
Asenapine—Hypersensitivity—Doxorubicin—thyroid cancer	0.0003	0.00104	CcSEcCtD
Asenapine—HTR2A—head—thyroid cancer	0.000299	0.0129	CbGeAlD
Asenapine—Asthenia—Doxorubicin—thyroid cancer	0.000292	0.00101	CcSEcCtD
Asenapine—Dizziness—Epirubicin—thyroid cancer	0.000291	0.00101	CcSEcCtD
Asenapine—Vomiting—Epirubicin—thyroid cancer	0.00028	0.00097	CcSEcCtD
Asenapine—Rash—Epirubicin—thyroid cancer	0.000278	0.000962	CcSEcCtD
Asenapine—Dermatitis—Epirubicin—thyroid cancer	0.000277	0.000961	CcSEcCtD
Asenapine—Headache—Epirubicin—thyroid cancer	0.000276	0.000956	CcSEcCtD
Asenapine—CYP2D6—head—thyroid cancer	0.000273	0.0117	CbGeAlD
Asenapine—Dizziness—Doxorubicin—thyroid cancer	0.000269	0.000934	CcSEcCtD
Asenapine—Nausea—Epirubicin—thyroid cancer	0.000262	0.000906	CcSEcCtD
Asenapine—Vomiting—Doxorubicin—thyroid cancer	0.000259	0.000898	CcSEcCtD
Asenapine—Rash—Doxorubicin—thyroid cancer	0.000257	0.00089	CcSEcCtD
Asenapine—Dermatitis—Doxorubicin—thyroid cancer	0.000257	0.000889	CcSEcCtD
Asenapine—Headache—Doxorubicin—thyroid cancer	0.000255	0.000885	CcSEcCtD
Asenapine—HRH1—lymph node—thyroid cancer	0.000251	0.0108	CbGeAlD
Asenapine—ADRA2A—lymph node—thyroid cancer	0.000247	0.0106	CbGeAlD
Asenapine—Nausea—Doxorubicin—thyroid cancer	0.000242	0.000839	CcSEcCtD
Asenapine—HTR6—GPCR downstream signaling—AKT1—thyroid cancer	2.24e-05	0.000131	CbGpPWpGaD
Asenapine—HTR1B—Signaling by GPCR—HRAS—thyroid cancer	2.23e-05	0.00013	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—HIF1A—thyroid cancer	2.23e-05	0.00013	CbGpPWpGaD
Asenapine—HTR7—GPCR downstream signaling—AKT1—thyroid cancer	2.23e-05	0.00013	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	2.23e-05	0.00013	CbGpPWpGaD
Asenapine—HTR1D—GPCR downstream signaling—AKT1—thyroid cancer	2.22e-05	0.00013	CbGpPWpGaD
Asenapine—DRD4—Signaling by GPCR—HRAS—thyroid cancer	2.2e-05	0.000128	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—SLC5A5—thyroid cancer	2.2e-05	0.000128	CbGpPWpGaD
Asenapine—UGT1A4—Metabolism—AKT1—thyroid cancer	2.19e-05	0.000128	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—BRAF—thyroid cancer	2.19e-05	0.000128	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—RXRA—thyroid cancer	2.18e-05	0.000127	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—BRAF—thyroid cancer	2.18e-05	0.000127	CbGpPWpGaD
Asenapine—HTR1B—GPCR downstream signaling—AKT1—thyroid cancer	2.17e-05	0.000127	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TERT—thyroid cancer	2.17e-05	0.000127	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—CCND1—thyroid cancer	2.16e-05	0.000126	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—CCND1—thyroid cancer	2.15e-05	0.000126	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—CCND1—thyroid cancer	2.14e-05	0.000125	CbGpPWpGaD
Asenapine—DRD4—GPCR downstream signaling—AKT1—thyroid cancer	2.14e-05	0.000125	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—BRAF—thyroid cancer	2.12e-05	0.000124	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PPARG—thyroid cancer	2.11e-05	0.000123	CbGpPWpGaD
Asenapine—HTR2B—Signaling by GPCR—HRAS—thyroid cancer	2.1e-05	0.000123	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—CCND1—thyroid cancer	2.1e-05	0.000122	CbGpPWpGaD
Asenapine—ADRB1—Signaling by GPCR—KRAS—thyroid cancer	2.09e-05	0.000122	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—KRAS—thyroid cancer	2.08e-05	0.000122	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—PTEN—thyroid cancer	2.08e-05	0.000121	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—TP53—thyroid cancer	2.08e-05	0.000121	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—PTEN—thyroid cancer	2.08e-05	0.000121	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—HIF1A—thyroid cancer	2.08e-05	0.000121	CbGpPWpGaD
Asenapine—ADRA2B—Signaling by GPCR—KRAS—thyroid cancer	2.07e-05	0.000121	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—PTEN—thyroid cancer	2.07e-05	0.000121	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—CCND1—thyroid cancer	2.06e-05	0.00012	CbGpPWpGaD
Asenapine—ADRA2A—Hemostasis—AKT1—thyroid cancer	2.06e-05	0.00012	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.06e-05	0.00012	CbGpPWpGaD
Asenapine—ADRB2—Signaling by GPCR—KRAS—thyroid cancer	2.05e-05	0.00012	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—PTGS2—thyroid cancer	2.04e-05	0.000119	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—NRAS—thyroid cancer	2.04e-05	0.000119	CbGpPWpGaD
Asenapine—HTR2B—GPCR downstream signaling—AKT1—thyroid cancer	2.04e-05	0.000119	CbGpPWpGaD
Asenapine—HTR6—Signaling by GPCR—AKT1—thyroid cancer	2.03e-05	0.000119	CbGpPWpGaD
Asenapine—HTR7—Signaling by GPCR—AKT1—thyroid cancer	2.03e-05	0.000118	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—PTEN—thyroid cancer	2.02e-05	0.000118	CbGpPWpGaD
Asenapine—HTR1D—Signaling by GPCR—AKT1—thyroid cancer	2.02e-05	0.000118	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—NRAS—thyroid cancer	2.01e-05	0.000117	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—NRAS—thyroid cancer	2.01e-05	0.000117	CbGpPWpGaD
Asenapine—HTR1A—Signaling by GPCR—KRAS—thyroid cancer	2e-05	0.000117	CbGpPWpGaD
Asenapine—HTR2C—Signaling by GPCR—KRAS—thyroid cancer	1.99e-05	0.000116	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—PTEN—thyroid cancer	1.99e-05	0.000116	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—HRAS—thyroid cancer	1.99e-05	0.000116	CbGpPWpGaD
Asenapine—DRD1—Signaling by GPCR—HRAS—thyroid cancer	1.98e-05	0.000116	CbGpPWpGaD
Asenapine—HTR1B—Signaling by GPCR—AKT1—thyroid cancer	1.97e-05	0.000115	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—CCND1—thyroid cancer	1.97e-05	0.000115	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—NRAS—thyroid cancer	1.97e-05	0.000115	CbGpPWpGaD
Asenapine—DRD3—Signaling by GPCR—HRAS—thyroid cancer	1.95e-05	0.000114	CbGpPWpGaD
Asenapine—DRD4—Signaling by GPCR—AKT1—thyroid cancer	1.94e-05	0.000113	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—KRAS—thyroid cancer	1.94e-05	0.000113	CbGpPWpGaD
Asenapine—DRD1—GPCR downstream signaling—AKT1—thyroid cancer	1.93e-05	0.000112	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—BRAF—thyroid cancer	1.92e-05	0.000112	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—PTEN—thyroid cancer	1.9e-05	0.000111	CbGpPWpGaD
Asenapine—DRD3—GPCR downstream signaling—AKT1—thyroid cancer	1.9e-05	0.000111	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—BRAF—thyroid cancer	1.89e-05	0.00011	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—BRAF—thyroid cancer	1.89e-05	0.00011	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—NRAS—thyroid cancer	1.86e-05	0.000108	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—CCND1—thyroid cancer	1.86e-05	0.000108	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—NRAS—thyroid cancer	1.86e-05	0.000108	CbGpPWpGaD
Asenapine—HTR2B—Signaling by GPCR—AKT1—thyroid cancer	1.85e-05	0.000108	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—TP53—thyroid cancer	1.85e-05	0.000108	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—BRAF—thyroid cancer	1.85e-05	0.000108	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—RXRA—thyroid cancer	1.85e-05	0.000108	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—NRAS—thyroid cancer	1.84e-05	0.000108	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—CCND1—thyroid cancer	1.83e-05	0.000107	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—NRAS—thyroid cancer	1.83e-05	0.000107	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—NRAS—thyroid cancer	1.8e-05	0.000105	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.8e-05	0.000105	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—PTEN—thyroid cancer	1.79e-05	0.000105	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—PTEN—thyroid cancer	1.78e-05	0.000104	CbGpPWpGaD
Asenapine—ADRB1—Signaling by GPCR—HRAS—thyroid cancer	1.78e-05	0.000104	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—NRAS—thyroid cancer	1.78e-05	0.000104	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—HRAS—thyroid cancer	1.77e-05	0.000103	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—PTEN—thyroid cancer	1.77e-05	0.000103	CbGpPWpGaD
Asenapine—ADRA2B—Signaling by GPCR—HRAS—thyroid cancer	1.76e-05	0.000103	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—KRAS—thyroid cancer	1.76e-05	0.000103	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—AKT1—thyroid cancer	1.76e-05	0.000102	CbGpPWpGaD
Asenapine—DRD1—Signaling by GPCR—AKT1—thyroid cancer	1.75e-05	0.000102	CbGpPWpGaD
Asenapine—ADRB2—Signaling by GPCR—HRAS—thyroid cancer	1.74e-05	0.000102	CbGpPWpGaD
Asenapine—ADRB1—GPCR downstream signaling—AKT1—thyroid cancer	1.73e-05	0.000101	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	1.73e-05	0.000101	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—KRAS—thyroid cancer	1.73e-05	0.000101	CbGpPWpGaD
Asenapine—DRD3—Signaling by GPCR—AKT1—thyroid cancer	1.72e-05	0.000101	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—BRAF—thyroid cancer	1.72e-05	0.0001	CbGpPWpGaD
Asenapine—ADRA2B—GPCR downstream signaling—AKT1—thyroid cancer	1.71e-05	0.0001	CbGpPWpGaD
Asenapine—HTR1A—Signaling by GPCR—HRAS—thyroid cancer	1.7e-05	9.94e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.7e-05	9.89e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—NRAS—thyroid cancer	1.7e-05	9.89e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—KRAS—thyroid cancer	1.69e-05	9.89e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling by GPCR—HRAS—thyroid cancer	1.69e-05	9.88e-05	CbGpPWpGaD
Asenapine—ADRB2—GPCR downstream signaling—AKT1—thyroid cancer	1.69e-05	9.88e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—CCND1—thyroid cancer	1.67e-05	9.74e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PTGS2—thyroid cancer	1.66e-05	9.69e-05	CbGpPWpGaD
Asenapine—HTR1A—GPCR downstream signaling—AKT1—thyroid cancer	1.66e-05	9.66e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—CCND1—thyroid cancer	1.65e-05	9.65e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—HRAS—thyroid cancer	1.65e-05	9.61e-05	CbGpPWpGaD
Asenapine—HTR2C—GPCR downstream signaling—AKT1—thyroid cancer	1.65e-05	9.61e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—CCND1—thyroid cancer	1.63e-05	9.53e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—PTEN—thyroid cancer	1.61e-05	9.4e-05	CbGpPWpGaD
Asenapine—ADRA2C—GPCR downstream signaling—AKT1—thyroid cancer	1.6e-05	9.35e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—NRAS—thyroid cancer	1.6e-05	9.33e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—KRAS—thyroid cancer	1.6e-05	9.33e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—KRAS—thyroid cancer	1.6e-05	9.32e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—CCND1—thyroid cancer	1.6e-05	9.32e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—PTEN—thyroid cancer	1.6e-05	9.32e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—CCND1—thyroid cancer	1.59e-05	9.27e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—KRAS—thyroid cancer	1.59e-05	9.26e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—NRAS—thyroid cancer	1.58e-05	9.21e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—PTEN—thyroid cancer	1.58e-05	9.2e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—KRAS—thyroid cancer	1.57e-05	9.19e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling by GPCR—AKT1—thyroid cancer	1.57e-05	9.17e-05	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—AKT1—thyroid cancer	1.56e-05	9.13e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling by GPCR—AKT1—thyroid cancer	1.56e-05	9.09e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—KRAS—thyroid cancer	1.55e-05	9.06e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—CCND1—thyroid cancer	1.54e-05	9.02e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—PTEN—thyroid cancer	1.54e-05	8.99e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling by GPCR—AKT1—thyroid cancer	1.54e-05	8.97e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—PTEN—thyroid cancer	1.53e-05	8.95e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—KRAS—thyroid cancer	1.53e-05	8.92e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling by GPCR—AKT1—thyroid cancer	1.5e-05	8.77e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling by GPCR—AKT1—thyroid cancer	1.5e-05	8.73e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—HRAS—thyroid cancer	1.49e-05	8.72e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—PTEN—thyroid cancer	1.49e-05	8.7e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	1.47e-05	8.58e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—HRAS—thyroid cancer	1.47e-05	8.57e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—KRAS—thyroid cancer	1.46e-05	8.52e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—AKT1—thyroid cancer	1.45e-05	8.49e-05	CbGpPWpGaD
Asenapine—DRD2—GPCR downstream signaling—AKT1—thyroid cancer	1.45e-05	8.48e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PTEN—thyroid cancer	1.45e-05	8.45e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—HRAS—thyroid cancer	1.44e-05	8.4e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—NRAS—thyroid cancer	1.44e-05	8.39e-05	CbGpPWpGaD
Asenapine—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	1.43e-05	8.35e-05	CbGpPWpGaD
Asenapine—HRH1—GPCR downstream signaling—AKT1—thyroid cancer	1.43e-05	8.33e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—RXRA—thyroid cancer	1.42e-05	8.31e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—NRAS—thyroid cancer	1.42e-05	8.31e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—TP53—thyroid cancer	1.42e-05	8.29e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—TP53—thyroid cancer	1.42e-05	8.28e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—TP53—thyroid cancer	1.41e-05	8.23e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—NRAS—thyroid cancer	1.41e-05	8.2e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CCND1—thyroid cancer	1.4e-05	8.18e-05	CbGpPWpGaD
Asenapine—ADRA1A—GPCR downstream signaling—AKT1—thyroid cancer	1.4e-05	8.17e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—TP53—thyroid cancer	1.38e-05	8.06e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CCND1—thyroid cancer	1.38e-05	8.05e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CCND1—thyroid cancer	1.38e-05	8.03e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—KRAS—thyroid cancer	1.38e-05	8.03e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PPARG—thyroid cancer	1.38e-05	8.03e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—NRAS—thyroid cancer	1.37e-05	8.02e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—NRAS—thyroid cancer	1.37e-05	7.98e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—HRAS—thyroid cancer	1.36e-05	7.93e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—TP53—thyroid cancer	1.36e-05	7.93e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—KRAS—thyroid cancer	1.36e-05	7.92e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—HRAS—thyroid cancer	1.36e-05	7.92e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PTEN—thyroid cancer	1.35e-05	7.9e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CCND1—thyroid cancer	1.35e-05	7.88e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—HRAS—thyroid cancer	1.35e-05	7.87e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—HRAS—thyroid cancer	1.34e-05	7.81e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PTEN—thyroid cancer	1.33e-05	7.77e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—NRAS—thyroid cancer	1.33e-05	7.76e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PTEN—thyroid cancer	1.33e-05	7.75e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—HRAS—thyroid cancer	1.32e-05	7.7e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—AKT1—thyroid cancer	1.32e-05	7.7e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PTEN—thyroid cancer	1.3e-05	7.61e-05	CbGpPWpGaD
Asenapine—ADRA2A—GPCR downstream signaling—AKT1—thyroid cancer	1.3e-05	7.59e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—HRAS—thyroid cancer	1.3e-05	7.58e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	1.3e-05	7.58e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—TP53—thyroid cancer	1.3e-05	7.57e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—AKT1—thyroid cancer	1.3e-05	7.56e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—AKT1—thyroid cancer	1.27e-05	7.42e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CCND1—thyroid cancer	1.25e-05	7.32e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—HRAS—thyroid cancer	1.24e-05	7.24e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—KRAS—thyroid cancer	1.24e-05	7.22e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—KRAS—thyroid cancer	1.23e-05	7.15e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—TP53—thyroid cancer	1.22e-05	7.14e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PTEN—thyroid cancer	1.21e-05	7.07e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—KRAS—thyroid cancer	1.21e-05	7.06e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—NRAS—thyroid cancer	1.21e-05	7.04e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—TP53—thyroid cancer	1.21e-05	7.04e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—AKT1—thyroid cancer	1.2e-05	7e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—AKT1—thyroid cancer	1.2e-05	6.99e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—AKT1—thyroid cancer	1.19e-05	6.95e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—NRAS—thyroid cancer	1.19e-05	6.93e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—NRAS—thyroid cancer	1.19e-05	6.92e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—KRAS—thyroid cancer	1.18e-05	6.91e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—AKT1—thyroid cancer	1.18e-05	6.9e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—KRAS—thyroid cancer	1.18e-05	6.87e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—HRAS—thyroid cancer	1.17e-05	6.83e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—AKT1—thyroid cancer	1.17e-05	6.8e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PPARG—thyroid cancer	1.17e-05	6.8e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—NRAS—thyroid cancer	1.16e-05	6.79e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—HRAS—thyroid cancer	1.15e-05	6.73e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—AKT1—thyroid cancer	1.15e-05	6.69e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—KRAS—thyroid cancer	1.14e-05	6.68e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TP53—thyroid cancer	1.1e-05	6.42e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—AKT1—thyroid cancer	1.1e-05	6.39e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TP53—thyroid cancer	1.09e-05	6.36e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTGS2—thyroid cancer	1.08e-05	6.32e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—NRAS—thyroid cancer	1.08e-05	6.31e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TP53—thyroid cancer	1.08e-05	6.28e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TP53—thyroid cancer	1.05e-05	6.14e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—HRAS—thyroid cancer	1.05e-05	6.14e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TP53—thyroid cancer	1.05e-05	6.11e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—HRAS—thyroid cancer	1.04e-05	6.08e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—KRAS—thyroid cancer	1.04e-05	6.06e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—AKT1—thyroid cancer	1.03e-05	6.03e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—HRAS—thyroid cancer	1.03e-05	6e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—AKT1—thyroid cancer	1.03e-05	6e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—KRAS—thyroid cancer	1.02e-05	5.97e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—KRAS—thyroid cancer	1.02e-05	5.95e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—AKT1—thyroid cancer	1.02e-05	5.95e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TP53—thyroid cancer	1.02e-05	5.94e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—HRAS—thyroid cancer	1.01e-05	5.87e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—KRAS—thyroid cancer	1e-05	5.84e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—HRAS—thyroid cancer	1e-05	5.84e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—HRAS—thyroid cancer	9.73e-06	5.68e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTEN—thyroid cancer	9.44e-06	5.51e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—KRAS—thyroid cancer	9.3e-06	5.43e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—AKT1—thyroid cancer	9.28e-06	5.42e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TP53—thyroid cancer	9.23e-06	5.39e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—AKT1—thyroid cancer	9.2e-06	5.37e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTGS2—thyroid cancer	9.17e-06	5.35e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TP53—thyroid cancer	9.09e-06	5.3e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—AKT1—thyroid cancer	9.08e-06	5.3e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TP53—thyroid cancer	9.07e-06	5.29e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PPARG—thyroid cancer	8.99e-06	5.25e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TP53—thyroid cancer	8.9e-06	5.19e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—AKT1—thyroid cancer	8.88e-06	5.18e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—AKT1—thyroid cancer	8.83e-06	5.16e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—HRAS—thyroid cancer	8.83e-06	5.15e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—HRAS—thyroid cancer	8.69e-06	5.07e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—HRAS—thyroid cancer	8.67e-06	5.06e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—AKT1—thyroid cancer	8.59e-06	5.01e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—HRAS—thyroid cancer	8.51e-06	4.96e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—AKT1—thyroid cancer	8.35e-06	4.87e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TP53—thyroid cancer	8.27e-06	4.82e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTEN—thyroid cancer	8e-06	4.67e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—HRAS—thyroid cancer	7.9e-06	4.61e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—AKT1—thyroid cancer	7.8e-06	4.55e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—AKT1—thyroid cancer	7.67e-06	4.48e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—AKT1—thyroid cancer	7.66e-06	4.47e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—AKT1—thyroid cancer	7.51e-06	4.38e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTGS2—thyroid cancer	7.08e-06	4.13e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—AKT1—thyroid cancer	6.98e-06	4.07e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTEN—thyroid cancer	6.17e-06	3.6e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—AKT1—thyroid cancer	5.44e-06	3.17e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—AKT1—thyroid cancer	4.61e-06	2.69e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—AKT1—thyroid cancer	3.56e-06	2.08e-05	CbGpPWpGaD
